Market Intel: Opportunities for Medtech In Mental Health (Part 1) – Transcranial Magnetic Stimulation
Executive Summary
With the global pandemic leading to a big rise in mental health issues, medtech could have a role to play. In this first part of a two-part series focusing on mental health tech, Medtech Insight focuses on transcranial magnetic stimulation systems used to treat severe anxiety and depression, among other indications. Part two will focus on the skyrocketing use of telehealth, apps and light therapy.
You may also be interested in...
Execs On The Move: Management, Marketing Changes At Medtronic And Brainsway; New CEO At Tactile Medical
A new CMO and VP is selected at Medtronic’s Coronary and Structural Heart division; Brainsway, a developer of neuromodulation products, decides on a VP for global marketing; Tactile Medical, offering treatments for lymphedema and venous ulcers; announced a new CEO; and more.
OCD Indication Approved For Brainsway TMS Device
US FDA used its de novo review pathway to approve Brainsway Ltd.’s Brainsway Deep Transcranial Magnetic Stimulation System to treat obsessive compulsive disorder.
JPM 2022: Boston Scientific, Inspire, Nuvasive, Vericel
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the third day of the meeting.